Viewing Study NCT04254042



Ignite Creation Date: 2024-05-06 @ 2:14 PM
Last Modification Date: 2024-10-26 @ 1:27 PM
Study NCT ID: NCT04254042
Status: COMPLETED
Last Update Posted: 2020-02-05
First Post: 2020-01-31

Brief Title: Comparative Effects of Perindopril and Zofenopril on Blood Pressure Control and Oxidative Status Blacks Hypertensive Patients
Sponsor: Yaounde Central Hospital
Organization: Yaounde Central Hospital

Study Overview

Official Title: Rationale and Design of a Simple Randomized Trial Evaluating Comparative Effects of Perindopril and Zofenopril in Blacks Hypertensive Patients Short Term Effects on Cardiac and Oxidative Status With Perindopril or Zofenopril PEZO-HP Trial
Status: COMPLETED
Status Verified Date: 2020-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: PEZO-HP
Brief Summary: The aim of the study is to compare the short term effect of perindopril and zofenopril in the management of hypertension and the oxydative stress in blacks hypertensive patients

PEZO-HP is a double-arm double-blind randomized and parallel clinical trial conducted at the Yaoundé Central Hospital
Detailed Description: Aim to determine and compare the short term effect of angiotensin converting in the management of hypertension as well as the oxidative effect of Zofenopril and perindopril in blacks hypertensive patients in the Yaoundé Central Hospital

Method A double-arm double-blind randomized and parallel clinical trial conducted at the Yaoundé Central Hospital Hypertensive patients who are not taking angiotensin-converting enzyme inhibitor or angiotensin receptors blockers are randomize into 2 groups Depending on the group the intervention consisted of the administration of Perindopril 10 mg daily or Zofenopril 30 mg daily for 08 weeks The endpoints were the nycthemeral blood pressure profile pro oxidant marker malondialdehyde and anti-oxidant marker Ferric reducing antioxidant

Progress Recruitment for PEZO-HP was completed in May 2019 with 24 patients

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: None